PADI4 and multiple sclerosis: Preceding studies have demonstrated the protective effects of PAD inhibitors on the models of SLE (27) and other NET-related diseases, including multiple sclerosis (39), collagen-induced arthritis (40), and inflammatory bowel disease (41).